期刊
CANCER RESEARCH
卷 77, 期 9, 页码 2191-2196出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-16-2523
关键词
-
类别
资金
- U.S. NIH [NCIK08 CA151682, NCI R01 CA076287, NCIR01 CA136639, NCIR01 CA154897, NCIP01 CA044991, NCIR21 CA155911, NCIR01 CA109663]
- Multiple Myeloma Opportunities for Research and Education (MMORE)
- Quest for Truth Foundation
- Brotherton Family Fund
- David and Patricia Giuliani Family Foundation
Therapy of cancer with radiolabeled monoclonal antibodies has produced impressive results in preclinical experiments and in clinical trials conducted in radiosensitive malignancies, particularly B-cell lymphomas. Two first-generation, directly radiolabeled anti-CD20 antibodies, (131)iodine-tositumomab and (90)yttrium-ibritumomab tiuxetan, were FDA-approved more than a decade ago but have been little utilized because of a variety of medical, financial, and logistic obstacles. Newer technologies employing multistep pretargeting methods, particularly those utilizing bispecific antibodies, have greatly enhanced the therapeutic efficacy of radioimmunotherapy and diminished its toxicities. The dramatically improved therapeutic index of bispecific antibody pretargeting appears to be sufficiently compelling to justify human clinical trials and reinvigorate enthusiasm for radioimmunotherapy in the treatment of malignancies, particularly lymphomas. (C) 2017 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据